Lilly's Amylin–Zepbound Combo Posts Record Weight Loss in Phase 2b, but Dropouts Rise
- EloraTZP combines the amylin agonist eloralintide with tirzepatide; in adults with obesity and type 2 diabetes it beat tirzepatide alone on weight loss and A1C at 48 weeks, with up to 23.3% weight loss at the top dose.
- Discontinuations due to adverse events were higher in the combination arms, mostly GI-related during dose escalation, which raises tolerability questions.
- Lilly plans to start phase 3 in the fourth quarter of 2026.
💡 Points
Beating retatrutide's diabetes-population number with an amylin add-on strengthens Lilly's case that obesity's next act is combinations, ahead of AbbVie and Pfizer amylin plays. The dropout rate is the real commercial variable: if titration cannot tame GI effects, a headline efficacy edge shrinks in practice. Phase 3 design, especially the dose-escalation schedule, will tell us how much of this is deliverable.